The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. [electronic resource]
Producer: 20110321Description: 1270-9 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antineoplastic Agents -- pharmacology
- Benzoquinones -- pharmacology
- Boronic Acids -- therapeutic use
- Bortezomib
- Cell Survival -- drug effects
- Down-Regulation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Endoplasmic Reticulum Chaperone BiP
- Female
- Gene Expression Regulation, Neoplastic -- drug effects
- Gene Knockdown Techniques
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Heat-Shock Proteins -- genetics
- Humans
- Lactams, Macrocyclic -- pharmacology
- Lymphoma, Mantle-Cell -- drug therapy
- Male
- Mice
- Mice, SCID
- Mice, Transgenic
- Middle Aged
- Molecular Chaperones -- genetics
- Pyrazines -- therapeutic use
- Receptors, Estrogen -- metabolism
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.